{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:22:43Z","timestamp":1792794163639,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40257-025-00977-1","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:20:40Z","timestamp":1756210840000},"page":"877-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review"],"prefix":"10.1007","volume":"26","author":[{"given":"Luca","family":"Mastorino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Frigatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Macagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"977_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-02078-3","author":"B Song","year":"2024","unstructured":"Song B, Ning X, Guo L, Liu W, Jin H. Comparative proteomics analysis reveals distinct molecular phenotype and biomarkers in patients with erythrodermic atopic dermatitis and erythrodermic psoriasis. Inflammation. 2024. https:\/\/doi.org\/10.1007\/s10753-024-02078-3.","journal-title":"Inflammation"},{"issue":"4","key":"977_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","volume":"62","author":"M Rosenbach","year":"2010","unstructured":"Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Van Voorhees AS, National Psoriasis Foundation Medical Board. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2009.05.048.","journal-title":"J Am Acad Dermatol"},{"key":"977_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/PTT.S101232","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, Abrouk M, Nakamura M, Zhu TH, Liao W. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93\u2013104. https:\/\/doi.org\/10.2147\/PTT.S101232.","journal-title":"Psoriasis (Auckl)."},{"issue":"9774","key":"977_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41598-020-66040-7","volume":"10","author":"D Miyashiro","year":"2020","unstructured":"Miyashiro D, Sanches JA. Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. Sci Rep. 2020;10(9774):3. https:\/\/doi.org\/10.1038\/s41598-020-66040-7.","journal-title":"Sci Rep"},{"issue":"6","key":"977_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ced.14625","volume":"46","author":"S Tso","year":"2021","unstructured":"Tso S, Satchwell F, Moiz H, et al. Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation and pathogenesis. Clin Exp Dermatol. 2021;46(6):1001\u201310. https:\/\/doi.org\/10.1111\/ced.14625.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"977_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/cyto.b.21888","volume":"100","author":"MP Pulitzer","year":"2021","unstructured":"Pulitzer MP, Horna P, Almeida J. S\u00e9zary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping. Cytometry B Clin Cytom. 2021;100(2):132\u20138. https:\/\/doi.org\/10.1002\/cyto.b.21888.","journal-title":"Cytometry B Clin Cytom"},{"key":"977_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamadermatol.2015.2","volume":"151","author":"AP Moy","year":"2015","unstructured":"Moy AP, Murali M, Kroshinsky D, et al. Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis. JAMA Dermatol. 2015;151:753\u201360. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2.","journal-title":"JAMA Dermatol"},{"key":"977_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-319-75623-3_19","volume-title":"Life-threatening rashes","author":"K Harper-Kirksey","year":"2018","unstructured":"Harper-Kirksey K. Erythroderma. In: Rose E, editor. Life-threatening rashes. Cham: Springer; 2018. p. 265\u201377."},{"issue":"16","key":"977_CR9","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2147\/CCID.S407813","volume":"4","author":"L Potestio","year":"2023","unstructured":"Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F, Battista T, Megna M. Biologics for the management of erythrodermic psoriasis: an updated review. Clin Cosmet Investig Dermatol. 2023;4(16):2045\u201359. https:\/\/doi.org\/10.2147\/CCID.S407813.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"977_CR10","first-page":"841","volume":"89","author":"A Hawilo","year":"2011","unstructured":"Hawilo A, Zaraa I, Benmously R, Mebazaa A, El Euch D, Mokni M, Ben Osman A. Erythrodermie psoriasique: profil \u00e9pid\u00e9mio-clinique et th\u00e9rapeutique \u00e0 propos de 60 cas [Erythrodermic psoriasis: epidemiological clinical and therapeutic features about 60 cases]. Tunis Med. 2011;89(11):841\u20137 (French).","journal-title":"Tunis Med"},{"issue":"3","key":"977_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/1346-8138.17074","volume":"51","author":"S Imafuku","year":"2024","unstructured":"Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, Shao Y, Banerjee S, Morita A. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial. J Dermatol. 2024;51(3):365\u201379. https:\/\/doi.org\/10.1111\/1346-8138.17074.","journal-title":"J Dermatol"},{"issue":"2","key":"977_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/1346-8138.16667","volume":"50","author":"K Yamanaka","year":"2023","unstructured":"Yamanaka K, Okubo Y, Yasuda I, Saito N, Messina I, Morita A. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study. J Dermatol. 2023;50(2):195\u2013202. https:\/\/doi.org\/10.1111\/1346-8138.16667.","journal-title":"J Dermatol"},{"issue":"6","key":"977_CR13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s13555-022-00741-x","volume":"12","author":"Y Okubo","year":"2022","unstructured":"Okubo Y, Umezawa Y, Sakurai S, Hoshii N, Nakagawa H. Efficacy and safety of certolizumab pegol in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 52-week results. Dermatol Ther (Heidelb). 2022;12(6):1397\u2013415. https:\/\/doi.org\/10.1007\/s13555-022-00741-x.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"977_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jdv.15287","volume":"33","author":"Y Okubo","year":"2019","unstructured":"Okubo Y, Mabuchi T, Iwatsuki K, Elmaraghy H, Torisu-Itakura H, Morisaki Y, Nakajo K. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33(2):325\u201332. https:\/\/doi.org\/10.1111\/jdv.15287.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"977_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1001\/archpedi.1968.02100020220018","volume":"116","author":"RB Scott","year":"1968","unstructured":"Scott RB, Surana R. Erythrodermic psoriasis in childhood. A young Negro child treated with methotrexate. Am J Dis Child. 1968;116(2):218\u201321. https:\/\/doi.org\/10.1001\/archpedi.1968.02100020220018.","journal-title":"Am J Dis Child"},{"issue":"1","key":"977_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/s0190-9622(86)70009-1","volume":"14","author":"E Tuyp","year":"1986","unstructured":"Tuyp E, MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol. 1986;14(1):70\u20133. https:\/\/doi.org\/10.1016\/s0190-9622(86)70009-1.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"977_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000248324","volume":"179","author":"MJ Korstanje","year":"1989","unstructured":"Korstanje MJ, Bessems PJ, van de Staak WJ. Combination therapy cyclosporine-etretinate effective in erythrodermic psoriasis. Dermatologica. 1989;179(2):94. https:\/\/doi.org\/10.1159\/000248324.","journal-title":"Dermatologica"},{"issue":"4","key":"977_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2230.1992.tb02161.x","volume":"17","author":"P Collins","year":"1992","unstructured":"Collins P, Rogers S. The efficacy of methotrexate in psoriasis\u2013a review of 40 cases. Clin Exp Dermatol. 1992;17(4):257\u201360. https:\/\/doi.org\/10.1111\/j.1365-2230.1992.tb02161.x.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"977_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1525-1470.1994.tb00602.x","volume":"11","author":"B Kumar","year":"1994","unstructured":"Kumar B, Dhar S, Handa S, Kaur I. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11(3):271\u20133. https:\/\/doi.org\/10.1111\/j.1525-1470.1994.tb00602.x.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"977_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2340\/00015555766567","volume":"76","author":"CJ van der Vleuten","year":"1996","unstructured":"van der Vleuten CJ, Gerritsen MJ, Steijlen PM, de Jong EM, van de Kerkhof PC. A therapeutic approach to erythrodermic psoriasis: report of a case and a discussion of therapeutic options. Acta Derm Venereol. 1996;76(1):65\u20137. https:\/\/doi.org\/10.2340\/00015555766567.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"977_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000246070","volume":"194","author":"AL Kuijpers","year":"1997","unstructured":"Kuijpers AL, van Dooren-Greebe JV, van de Kerkhof PC. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis. Dermatology. 1997;194(1):88\u201390. https:\/\/doi.org\/10.1159\/000246070.","journal-title":"Dermatology"},{"issue":"5","key":"977_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/000155599750010382","volume":"79","author":"T Peters","year":"1999","unstructured":"Peters T, Theile-Ochel S, Chemnitz J, S\u00f6hngen D, Hunzelmann N, Scharffetter-Kochanek K. Exfoliative dermatitis after long-term methotrexate treatment of severe psoriasis. Acta Derm Venereol. 1999;79(5):391\u20132. https:\/\/doi.org\/10.1080\/000155599750010382.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"977_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","volume":"14","author":"UF Haustein","year":"2000","unstructured":"Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years\u2019 experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14(5):382\u20138. https:\/\/doi.org\/10.1046\/j.1468-3083.2000.00058.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"977_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1001\/archderm.138.5.644","volume":"138","author":"RP O'Quinn","year":"2002","unstructured":"O\u2019Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol. 2002;138(5):644\u20138. https:\/\/doi.org\/10.1001\/archderm.138.5.644.","journal-title":"Arch Dermatol"},{"issue":"4","key":"977_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/09546630310010895","volume":"14","author":"F Rongioletti","year":"2003","unstructured":"Rongioletti F, Borenstein M, Kirsner R, Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat. 2003;14(4):222\u20135. https:\/\/doi.org\/10.1080\/09546630310010895.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"977_CR26","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.athoracsur.2003.06.035","volume":"79","author":"PK Jha","year":"2005","unstructured":"Jha PK, Das SR, Musleh GS, Lakshmanan S, Kingston TP, Deiraniya AK. Psoriasis-induced postoperative cardiac failure. Ann Thorac Surg. 2005;79(4):1390\u20131. https:\/\/doi.org\/10.1016\/j.athoracsur.2003.06.035.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"977_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1540-9740.2006.04515.x","volume":"5","author":"D Antonov","year":"2006","unstructured":"Antonov D, Grozdev I, Pehlivanov G, Tsankov N. Psoriatic erythroderma associated with enalapril. Skinmed. 2006;5(2):90\u20132. https:\/\/doi.org\/10.1111\/j.1540-9740.2006.04515.x.","journal-title":"Skinmed."},{"issue":"2","key":"977_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1525-1470.2008.00629.x","volume":"25","author":"I Kaur","year":"2008","unstructured":"Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25(2):184\u20138. https:\/\/doi.org\/10.1111\/j.1525-1470.2008.00629.x.","journal-title":"Pediatr Dermatol"},{"issue":"4 Suppl 1","key":"977_CR29","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1590\/s0365-05962011000700038","volume":"86","author":"NA Fraga","year":"2011","unstructured":"Fraga NA, Paim Mde F, Follador I, Ramos AN, R\u00eago VR. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatol. 2011;86(4 Suppl 1):S144\u20137. https:\/\/doi.org\/10.1590\/s0365-05962011000700038.","journal-title":"An Bras Dermatol"},{"issue":"5","key":"977_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1590\/abd1806-4841.20176565","volume":"92","author":"LA Tr\u00eddico","year":"2017","unstructured":"Tr\u00eddico LA, Antonio JR, Mathias CE, Pozetti EMO. Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis. An Bras Dermatol. 2017;92(5):743\u20135. https:\/\/doi.org\/10.1590\/abd1806-4841.20176565.","journal-title":"An Bras Dermatol"},{"issue":"2","key":"977_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000508781","volume":"12","author":"MCG Pangilinan","year":"2020","unstructured":"Pangilinan MCG, Sermswan P, Asawanonda P. Use of anti-IL-17 monoclonal antibodies in HIV patients with erythrodermic psoriasis. Case Rep Dermatol. 2020;12(2):132\u20137. https:\/\/doi.org\/10.1159\/000508781.","journal-title":"Case Rep Dermatol"},{"issue":"2","key":"977_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archderm.1982.01650140029013","volume":"118","author":"G Mahrle","year":"1982","unstructured":"Mahrle G, Meyer-Hamme S, Ippen H. Oral treatment of keratinizing disorders of skin and mucous membranes with etretinate. Comparative study of 113 patients. Arch Dermatol. 1982;118(2):97\u2013100.","journal-title":"Arch Dermatol"},{"issue":"6","key":"977_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s0190-9622(83)70203-3","volume":"9","author":"H Wolska","year":"1983","unstructured":"Wolska H, Jablonska S, Bounameaux Y. Etretinate in severe psoriasis. Results of double-blind study and maintenance therapy in pustular psoriasis. J Am Acad Dermatol. 1983;9(6):883\u20139. https:\/\/doi.org\/10.1016\/s0190-9622(83)70203-3.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"977_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1525-1470.1988.tb00902.x","volume":"5","author":"D Rosi\u0144ska","year":"1988","unstructured":"Rosi\u0144ska D, Wolska H, Jablonska S, Konca I. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5(4):266\u201372. https:\/\/doi.org\/10.1111\/j.1525-1470.1988.tb00902.x.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"977_CR35","first-page":"177","volume":"11","author":"F Kokelj","year":"1998","unstructured":"Kokelj F, Plozzer C, Torsello P, Trevisan G. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). J Eur Acad Dermatol Venereol. 1998;11(2):177\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"977_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1365-2133.2006.07270.x","volume":"155","author":"Y Kano","year":"2006","unstructured":"Kano Y, Teraki Y, Shiohara T. Dramatic improvement of psoriatic erythroderma after acute hepatitis: analysis of cytokine synthesis capability in peripheral blood T cells. Br J Dermatol. 2006;155(2):455\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07270.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"977_CR37","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11999-009-1010-8","volume":"468","author":"S Tsuji","year":"2010","unstructured":"Tsuji S, Tomita T, Inaoka M, Higashiyama M. Case report: psoriatic erythroderma with bilateral osseous bridge across the acetabulum. Clin Orthop Relat Res. 2010;468(4):1173\u20137. https:\/\/doi.org\/10.1007\/s11999-009-1010-8.","journal-title":"Clin Orthop Relat Res"},{"issue":"2","key":"977_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.radcr.2018.02.005","volume":"13","author":"R Kurokawa","year":"2018","unstructured":"Kurokawa R, Hagiwara A, Niijima Y, Kojima K. Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: A case report. Radiol Case Rep. 2018;13(2):460\u20133. https:\/\/doi.org\/10.1016\/j.radcr.2018.02.005.","journal-title":"Radiol Case Rep."},{"issue":"3","key":"977_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1525-1470.1995.tb00165.x","volume":"12","author":"M Salleras","year":"1995","unstructured":"Salleras M, Sanchez-Rega\u00f1a M, Umbert P. Congenital erythrodermic psoriasis: case report and literature review. Pediatr Dermatol. 1995;12(3):231\u20134. https:\/\/doi.org\/10.1111\/j.1525-1470.1995.tb00165.x.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"977_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1468-3083.1999.tb01027.x","volume":"12","author":"E Sprecher","year":"1999","unstructured":"Sprecher E, Bergman R, Friedman-Birnbaum R. Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis. J Eur Acad Dermatol Venereol. 1999;12(2):197\u20138. https:\/\/doi.org\/10.1111\/j.1468-3083.1999.tb01027.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"977_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3810\/pgm.2005.01.1577","volume":"117","author":"AN Jaffer","year":"2005","unstructured":"Jaffer AN, Brodell RT. Exfoliative dermatitis. Erythroderma can be a sign of a significant underlying disorder. Postgrad Med. 2005;117(1):49\u201351. https:\/\/doi.org\/10.3810\/pgm.2005.01.1577.","journal-title":"Postgrad Med"},{"issue":"4 Suppl 1","key":"977_CR42","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1590\/s0365-05962011000700037","volume":"86","author":"IP Redighieri","year":"2011","unstructured":"Redighieri IP, Maia Tde C, Nadal MA, Caliman TR, Ruiz Mde F, Petri V. Erythrodermic psoriasis with regression after prophylaxis with isoniazid and antidepressant therapy: case report. An Bras Dermatol. 2011;86(4 Suppl 1):S141\u20133. https:\/\/doi.org\/10.1590\/s0365-05962011000700037.","journal-title":"An Bras Dermatol"},{"key":"977_CR43","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1186\/1756-0500-7-929","volume":"7","author":"E Campione","year":"2014","unstructured":"Campione E, Diluvio L, Terrinoni A, et al. Severe erytrodermic psoriasis in child twins: from clinical-pathological diagnosis to treatment of choice through genetic analyses: two case reports. BMC Res Notes. 2014;7:929. https:\/\/doi.org\/10.1186\/1756-0500-7-929.","journal-title":"BMC Res Notes"},{"issue":"5","key":"977_CR44","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/bjd.14326","volume":"174","author":"L Charbit","year":"2016","unstructured":"Charbit L, Mah\u00e9 E, Phan A, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol. 2016;174(5):1118\u201321. https:\/\/doi.org\/10.1111\/bjd.14326.","journal-title":"Br J Dermatol"},{"issue":"3","key":"977_CR45","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1590\/abd1806-4841.20187387","volume":"93","author":"F Valenzuela","year":"2018","unstructured":"Valenzuela F, Fern\u00e1ndez J, S\u00e1nchez M, Zamudio A. Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges. An Bras Dermatol. 2018;93(3):438\u201340. https:\/\/doi.org\/10.1590\/abd1806-4841.20187387.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"977_CR46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/s0190-9622(87)70221-7","volume":"17","author":"DD Picascia","year":"1987","unstructured":"Picascia DD, Garden JM, Freinkel RK, Roenigk HH Jr. Treatment of resistant severe psoriasis with systemic cyclosporine. J Am Acad Dermatol. 1987;17(3):408\u201314. https:\/\/doi.org\/10.1016\/s0190-9622(87)70221-7.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"977_CR47","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/030006058801600611","volume":"16","author":"N Sutthipisal","year":"1988","unstructured":"Sutthipisal N, Sriwatsantsak J, Sirimachan S, Nitidandhabaprabhas P. The use of low dose cyclosporin A in a case of recalcitrant erythrodermic psoriasis. J Int Med Res. 1988;16(6):485\u20138. https:\/\/doi.org\/10.1177\/030006058801600611.","journal-title":"J Int Med Res"},{"key":"977_CR48","first-page":"151","volume":"146","author":"C Bonifati","year":"1989","unstructured":"Bonifati C, Clerico R, Potenza CM, Carlesimo M. Cyclosporin A: preliminary results in the treatment of psoriasis. Acta Derm Venereol Suppl (Stockh). 1989;146:151\u20134.","journal-title":"Acta Derm Venereol Suppl (Stockh)."},{"key":"977_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2340\/0001555569146159163","volume":"146","author":"A Cimitan","year":"1989","unstructured":"Cimitan A, Fantini F, Giannetti A. Clinical trial with cyclosporin A. Acta Derm Venereol Suppl (Stockh). 1989;146:159\u201363. https:\/\/doi.org\/10.2340\/0001555569146159163.","journal-title":"Acta Derm Venereol Suppl (Stockh)."},{"issue":"2 Pt 1","key":"977_CR50","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/s0190-9622(08)80749-9","volume":"27","author":"L Bianchi","year":"1992","unstructured":"Bianchi L, Gatti S, Nini G. Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids. J Am Acad Dermatol. 1992;27(2 Pt 1):278. https:\/\/doi.org\/10.1016\/s0190-9622(08)80749-9.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"977_CR51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000247289","volume":"187","author":"Management of erythrodermic psoriasis with low-dose cyclosporin","year":"1993","unstructured":"Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology. 1993;187(Suppl 1):30\u20137. https:\/\/doi.org\/10.1159\/000247289.","journal-title":"Dermatology"},{"issue":"12","key":"977_CR52","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/j.1365-4632.2012.05571.x","volume":"51","author":"A Borghi","year":"2012","unstructured":"Borghi A, Corazza M, Mantovani L, Bertoldi AM, Giari S, Virgili A. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients. Int J Dermatol. 2012;51(12):1512\u20136. https:\/\/doi.org\/10.1111\/j.1365-4632.2012.05571.x.","journal-title":"Int J Dermatol"},{"issue":"1","key":"977_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/09546634.2015.1034072","volume":"28","author":"S Dogra","year":"2017","unstructured":"Dogra S, Mahajan R, Narang T, Handa S. Systemic cyclosporine treatment in severe childhood psoriasis: a retrospective chart review. J Dermatolog Treat. 2017;28(1):18\u201320. https:\/\/doi.org\/10.3109\/09546634.2015.1034072.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"977_CR54","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/j.jemermed.2016.11.034","volume":"52","author":"PA Singh","year":"2017","unstructured":"Singh PA, Cassel KP, Moscati RM, Eckersley D. Acute generalized erythrodermic pustular psoriasis associated with bupropion\/naltrexone (Contrave\u00ae). J Emerg Med. 2017;52(4):e111\u20133. https:\/\/doi.org\/10.1016\/j.jemermed.2016.11.034.","journal-title":"J Emerg Med"},{"issue":"9","key":"977_CR55","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1111\/jdv.14234","volume":"31","author":"C Mugheddu","year":"2017","unstructured":"Mugheddu C, Atzori L, Lappi A, Pau M, Murgia S, Rongioletti F. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017;31(9):e420\u20131. https:\/\/doi.org\/10.1111\/jdv.14234.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"977_CR56","first-page":"141","volume":"72","author":"TL Tan","year":"2017","unstructured":"Tan TL, Chung WM. A case series of dermatological emergencies - Erythroderma. Med J Malaysia. 2017;72(2):141\u20133.","journal-title":"Med J Malaysia"},{"issue":"2","key":"977_CR57","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/09546634.2020.1799918","volume":"33","author":"F Ghalamkarpour","year":"2022","unstructured":"Ghalamkarpour F, Pourani MR, Abdollahimajd F, Zargari O. A case of severe psoriatic erythroderma with COVID-19. J Dermatolog Treat. 2022;33(2):1111\u20133. https:\/\/doi.org\/10.1080\/09546634.2020.1799918.","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"977_CR58","first-page":"1379","volume":"118","author":"GA Wasserman","year":"1978","unstructured":"Wasserman GA, Llewellyn MW, Ramsay CA, Haberman HF. Treatment of psoriasis with orally administered 8-methoxypsoralen and long-wavelength ultraviolet radiation. Can Med Assoc J. 1978;118(11):1379\u201383.","journal-title":"Can Med Assoc J"},{"issue":"8","key":"977_CR59","first-page":"1016","volume":"124","author":"JP DesGroseilliers","year":"1981","unstructured":"DesGroseilliers JP, Reilly SM, Cullen AE. The importance of patient selection for photochemotherapy in psoriasis. Can Med Assoc J. 1981;124(8):1016\u20138.","journal-title":"Can Med Assoc J"},{"issue":"2","key":"977_CR60","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2133.1993.tb15147.x","volume":"128","author":"E Snellman","year":"1993","unstructured":"Snellman E, Lauharanta J, Reunanen A, et al. Effect of heliotherapy on skin and joint symptoms in psoriasis: a 6-month follow-up study. Br J Dermatol. 1993;128(2):172\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.1993.tb15147.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"977_CR61","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.4081\/dr.2016.6599","volume":"8","author":"J Arcilla","year":"2016","unstructured":"Arcilla J, Joe D, Kim J, Kim Y, Truong VN, Jaipaul N. Erythrodermic psoriasis treated with apremilast. Dermatol Rep. 2016;8(1):6599. https:\/\/doi.org\/10.4081\/dr.2016.6599.","journal-title":"Dermatol Rep"},{"issue":"1","key":"977_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15204","volume":"35","author":"M Megna","year":"2022","unstructured":"Megna M, Ocampo-Garza SS, Fabbrocini G, Cinelli E, Ruggiero A, Camela E. A case of erythrodermic psoriasis successfully treated with apremilast. Dermatol Ther. 2022;35(1): e15204. https:\/\/doi.org\/10.1111\/dth.15204.","journal-title":"Dermatol Ther"},{"issue":"1","key":"977_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-226959","volume":"12","author":"G Krishnamoorthy","year":"2019","unstructured":"Krishnamoorthy G, Kotecha A, Pimentel J. Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy. BMJ Case Rep. 2019;12(1): e226959. https:\/\/doi.org\/10.1136\/bcr-2018-226959.","journal-title":"BMJ Case Rep"},{"issue":"11","key":"977_CR64","doi-asserted-by":"publisher","first-page":"e705","DOI":"10.1111\/jdv.16443","volume":"34","author":"M Megna","year":"2020","unstructured":"Megna M, Fabbrocini G, Camela E, Cinelli E. Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period. J Eur Acad Dermatol Venereol. 2020;34(11):e705\u20137. https:\/\/doi.org\/10.1111\/jdv.16443.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"977_CR65","doi-asserted-by":"publisher","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","volume":"35","author":"T Hagino","year":"2024","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. J Dermatolog Treat. 2024;35(1):2307489. https:\/\/doi.org\/10.1080\/09546634.2024.2307489.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"977_CR66","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/ard.2003.014191","volume":"63","author":"C Fiehn","year":"2004","unstructured":"Fiehn C, Andrassy K. Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis. 2004;63(3):232. https:\/\/doi.org\/10.1136\/ard.2003.014191.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"977_CR67","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/archderm.141.12.1607","volume":"141","author":"H Heikkil\u00e4","year":"2005","unstructured":"Heikkil\u00e4 H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005;141(12):1607\u201310. https:\/\/doi.org\/10.1001\/archderm.141.12.1607.","journal-title":"Arch Dermatol"},{"issue":"6","key":"977_CR68","first-page":"546","volume":"5","author":"TG Lewis","year":"2006","unstructured":"Lewis TG, Tuchinda C, Lim HW, Wong HK. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol. 2006;5(6):546\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"977_CR69","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2133.2006.07639.x","volume":"156","author":"N Poulalhon","year":"2007","unstructured":"Poulalhon N, Begon E, Lebb\u00e9 C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156(2):329\u201336. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07639.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"977_CR70","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1440-0960.2008.00463.x","volume":"49","author":"L Yip","year":"2008","unstructured":"Yip L, Harrison S, Foley P. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis. Australas J Dermatol. 2008;49(3):152\u20135. https:\/\/doi.org\/10.1111\/j.1440-0960.2008.00463.x.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"977_CR71","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1365-2133.2010.09669.x","volume":"162","author":"J Santos-Juanes","year":"2010","unstructured":"Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache OC. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010;162(5):1144\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09669.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"977_CR72","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1346-8138.2010.00971.x","volume":"38","author":"H Torii","year":"2011","unstructured":"Torii H, Nakagawa H. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38(4):321\u201334. https:\/\/doi.org\/10.1111\/j.1346-8138.2010.00971.x.","journal-title":"J Dermatol"},{"issue":"2","key":"977_CR73","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2133.2012.10940.x","volume":"167","author":"M Viguier","year":"2012","unstructured":"Viguier M, Pag\u00e8s C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167(2):417\u201323. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10940.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"977_CR74","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/1346-8138.13214","volume":"43","author":"H Torii","year":"2016","unstructured":"Torii H, Terui T, Matsukawa M, et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance. J Dermatol. 2016;43(7):767\u201378. https:\/\/doi.org\/10.1111\/1346-8138.13214.","journal-title":"J Dermatol"},{"issue":"2","key":"977_CR75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2340\/00015555-2495","volume":"97","author":"R Tsutsumi","year":"2017","unstructured":"Tsutsumi R, Yoshida Y, Yamamoto O. Imiquimod-induced Psoriatic Erythroderma Treated with Infliximab. Acta Derm Venereol. 2017;97(2):279\u201380. https:\/\/doi.org\/10.2340\/00015555-2495.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"977_CR76","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/1346-8138.13698","volume":"44","author":"H Torii","year":"2017","unstructured":"Torii H, Nakano M, Yano T, Kondo K, Nakagawa H, SPREAD Study Group. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study. J Dermatol. 2017;44(5):552\u20139. https:\/\/doi.org\/10.1111\/1346-8138.13698.","journal-title":"J Dermatol"},{"issue":"6","key":"977_CR77","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1590\/abd1806-4841.20177346","volume":"92","author":"AS Vacas","year":"2017","unstructured":"Vacas AS, Gomez-Santana LV, Torre AC, Galimberti RL. Reactivation of Chagas-Mazza disease during treatment with infliximab. An Bras Dermatol. 2017;92(6):899\u2013900. https:\/\/doi.org\/10.1590\/abd1806-4841.20177346.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"977_CR78","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2133.2006.07217.x","volume":"155","author":"M Esposito","year":"2006","unstructured":"Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155(1):156\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07217.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"977_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14922","volume":"34","author":"A Agarwal","year":"2021","unstructured":"Agarwal A, Panda M, Ray A. Complete remission of Psoriatic erythroderma using modified low dose etanercept in a HIV positive patient: a case report with review of literature. Dermatol Ther. 2021;34(3): e14922. https:\/\/doi.org\/10.1111\/dth.14922.","journal-title":"Dermatol Ther"},{"issue":"Suppl 1","key":"977_CR80","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1111\/j.1529-8019.2009.01266.x","volume":"22","author":"AG Richetta","year":"2009","unstructured":"Richetta AG, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther. 2009;22(Suppl 1):S16\u20138. https:\/\/doi.org\/10.1111\/j.1529-8019.2009.01266.x.","journal-title":"Dermatol Ther"},{"key":"977_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12551.10.1111\/dth.12551","author":"DM Kapoor","year":"2017","unstructured":"Kapoor DM, Tan KW. Erythrodermic psoriasis peculiarly sparing anti-TNF injection sites in a patient with secondary loss of efficacy. Dermatol Ther. 2017. https:\/\/doi.org\/10.1111\/dth.12551.10.1111\/dth.12551.","journal-title":"Dermatol Ther"},{"issue":"3","key":"977_CR82","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/ajd.14292","volume":"65","author":"M Costa Blasco","year":"2024","unstructured":"Costa Blasco M, Doyle C, Diong S, Ni RS. Use of biologics for psoriasis in solid organ transplant recipients. Australas J Dermatol. 2024;65(3):276\u20139. https:\/\/doi.org\/10.1111\/ajd.14292.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"977_CR83","doi-asserted-by":"publisher","first-page":"446","DOI":"10.5021\/ad.2015.27.4.446","volume":"27","author":"WK Lee","year":"2015","unstructured":"Lee WK, Kim GW, Cho HH, et al. Erythrodermic Psoriasis Treated with Golimumab: A Case Report. Ann Dermatol. 2015;27(4):446\u20139. https:\/\/doi.org\/10.5021\/ad.2015.27.4.446.","journal-title":"Ann Dermatol"},{"issue":"11","key":"977_CR84","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1346-8138.2011.01224.x","volume":"38","author":"TS Wang","year":"2011","unstructured":"Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011;38(11):1096\u20139. https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01224.x.","journal-title":"J Dermatol"},{"issue":"3","key":"977_CR85","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1529-8019.2012.01465.x","volume":"25","author":"G Buggiani","year":"2012","unstructured":"Buggiani G, D\u2019Erme AM, Krysenka A, Pescitelli L, Lotti T, Prignano F. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail. Dermatol Ther. 2012;25(3):283\u20135. https:\/\/doi.org\/10.1111\/j.1529-8019.2012.01465.x.","journal-title":"Dermatol Ther"},{"issue":"8","key":"977_CR86","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1346-8138.2011.01499.x","volume":"39","author":"I Casti\u00f1eiras","year":"2012","unstructured":"Casti\u00f1eiras I, Fern\u00e1ndez-Diaz L, Ju\u00e1rez Y, Lueiro M. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012;39(8):730\u20131. https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01499.x.","journal-title":"J Dermatol"},{"issue":"3","key":"977_CR87","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000348645","volume":"5","author":"R Saraceno","year":"2013","unstructured":"Saraceno R, Talamonti M, Galluzzo M, Chiricozzi A, Costanzo A, Chimenti S. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol. 2013;5(3):254\u20139. https:\/\/doi.org\/10.1159\/000348645.","journal-title":"Case Rep Dermatol"},{"issue":"3","key":"977_CR88","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1684\/ejd.2014.2325","volume":"24","author":"G Stinco","year":"2014","unstructured":"Stinco G, Piccirillo A, Errichetti E, Bergamo S, Patrone P. Treatment of recalcitrant erythrodermic psoriasis with ustekinumab. Eur J Dermatol. 2014;24(3):387\u201390. https:\/\/doi.org\/10.1684\/ejd.2014.2325.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"977_CR89","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/dth.12131","volume":"27","author":"XA Koutsoukou","year":"2014","unstructured":"Koutsoukou XA, Papadavid E, Theodoropoulos K, Rigopoulos D. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission. Dermatol Ther. 2014;27(5):257\u20139. https:\/\/doi.org\/10.1111\/dth.12131.","journal-title":"Dermatol Ther"},{"issue":"4","key":"977_CR90","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1684\/ejd.2014.2386","volume":"24","author":"E Errichetti","year":"2014","unstructured":"Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol. 2014;24(4):508\u20139. https:\/\/doi.org\/10.1684\/ejd.2014.2386.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"977_CR91","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jdermsci.2015.01.005","volume":"78","author":"L Pescitelli","year":"2015","unstructured":"Pescitelli L, Dini V, Gisondi P, et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci. 2015;78(2):149\u201351. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.01.005.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"977_CR92","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5021\/ad.2016.28.1.121","volume":"28","author":"YS Kim","year":"2016","unstructured":"Kim YS, Kim HJ, Lee S, Park YL. Erythrodermic psoriasis improved by ustekinumab: a report of two cases. Ann Dermatol. 2016;28(1):121\u20132. https:\/\/doi.org\/10.5021\/ad.2016.28.1.121.","journal-title":"Ann Dermatol"},{"issue":"4","key":"977_CR93","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1111\/ijd.13273","volume":"55","author":"RA el-Azhary","year":"2016","unstructured":"el-Azhary RA, Lehman JS. Exfoliative erythroderma after tumor necrosis factor-\u03b1 inhibitor therapy. Int J Dermatol. 2016;55(4):e214\u20135. https:\/\/doi.org\/10.1111\/ijd.13273.","journal-title":"Int J Dermatol"},{"issue":"6","key":"977_CR94","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/jcm8060770","volume":"8","author":"G Damiani","year":"2019","unstructured":"Damiani G, Pacifico A, Russo F, et al. Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study. J Clin Med. 2019;8(6):770. https:\/\/doi.org\/10.3390\/jcm8060770.","journal-title":"J Clin Med"},{"issue":"6","key":"977_CR95","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/bjd.16252","volume":"178","author":"HJ Weng","year":"2018","unstructured":"Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2018;178(6):1439\u201340. https:\/\/doi.org\/10.1111\/bjd.16252.","journal-title":"Br J Dermatol"},{"issue":"4","key":"977_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12607","volume":"31","author":"A Mateu-Puchades","year":"2018","unstructured":"Mateu-Puchades A, Santos-Alarc\u00f3n S, Martorell-Calatayud A, Pujol-Marco C, S\u00e1nchez-Carazo JL. Erythrodermic psoriasis and secukinumab: Our clinical experience. Dermatol Ther. 2018;31(4): e12607. https:\/\/doi.org\/10.1111\/dth.12607.","journal-title":"Dermatol Ther"},{"issue":"4","key":"977_CR97","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1684\/ejd.2018.3327","volume":"28","author":"E Mashima","year":"2018","unstructured":"Mashima E, Sawada Y, Yamaguchi T, et al. Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration. Eur J Dermatol. 2018;28(4):539\u201340. https:\/\/doi.org\/10.1684\/ejd.2018.3327.","journal-title":"Eur J Dermatol"},{"key":"977_CR98","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1524818","author":"M Galluzzo","year":"2018","unstructured":"Galluzzo M, D\u2019Adamio S, Campione E, Mazzilli S, Bianchi L, Talamonti M. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. J Dermatolog Treat. 2018. https:\/\/doi.org\/10.1080\/09546634.2018.1524818.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"977_CR99","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1111\/1346-8138.14649","volume":"46","author":"T Shibata","year":"2019","unstructured":"Shibata T, Muto J, Takama H, Yanagishita T, Ito T, Watanabe D. Case of psoriatic erythroderma induced by the discontinuation of the chronic use of topical steroid after dialysis initiation and successfully treated with secukinumab. J Dermatol. 2019;46(4):e119\u201320. https:\/\/doi.org\/10.1111\/1346-8138.14649.","journal-title":"J Dermatol"},{"issue":"5","key":"977_CR100","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/bjd.18174","volume":"181","author":"Y Lo","year":"2019","unstructured":"Lo Y, Tsai TF. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series. Br J Dermatol. 2019;181(5):1106\u20137. https:\/\/doi.org\/10.1111\/bjd.18174.","journal-title":"Br J Dermatol"},{"issue":"3","key":"977_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13348","volume":"33","author":"L Pizzatti","year":"2020","unstructured":"Pizzatti L, Mugheddu C, Sanna S, Atzori L, Rongioletti F. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatol Ther. 2020;33(3): e13348. https:\/\/doi.org\/10.1111\/dth.13348.","journal-title":"Dermatol Ther"},{"issue":"11","key":"977_CR102","doi-asserted-by":"publisher","first-page":"300060520969494","DOI":"10.1177\/0300060520969494","volume":"48","author":"J Lu","year":"2020","unstructured":"Lu J, Tang S, Yu N, Yi X, Li Y. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report. J Int Med Res. 2020;48(11):300060520969494. https:\/\/doi.org\/10.1177\/0300060520969494.","journal-title":"J Int Med Res"},{"issue":"7","key":"977_CR103","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1097\/RHU.0000000000001401","volume":"27","author":"ZH Liu","year":"2021","unstructured":"Liu ZH, Shen H. Methotrexate-induced pneumonitis in a patient with psoriatic arthritis and erythroderma. J Clin Rheumatol. 2021;27(7):e260\u20131. https:\/\/doi.org\/10.1097\/RHU.0000000000001401.","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"977_CR104","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14865","volume":"34","author":"I Ozcan","year":"2021","unstructured":"Ozcan I, Karadag AS, Ceren E, Demirci B, Cebeci F. A case of erythrodermic psoriasis in which adalimumab injection sites are preserved. Dermatol Ther. 2021;34(2): e14865. https:\/\/doi.org\/10.1111\/dth.14865.","journal-title":"Dermatol Ther"},{"key":"977_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33393\/dti.2022.2355","volume":"16","author":"M Carriero","year":"2022","unstructured":"Carriero M. Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report. Drug Target Insights. 2022;16:1\u20135. https:\/\/doi.org\/10.33393\/dti.2022.2355.","journal-title":"Drug Target Insights."},{"issue":"7","key":"977_CR106","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1111\/jdv.18069","volume":"36","author":"G Avallone","year":"2022","unstructured":"Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022;36(7):e574\u20136. https:\/\/doi.org\/10.1111\/jdv.18069.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"977_CR107","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15684","volume":"35","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Zhang X, Wang R, Wang Y, Gong L, Li C. Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: a case report and brief literature review. Dermatol Ther. 2022;35(9): e15684. https:\/\/doi.org\/10.1111\/dth.15684.","journal-title":"Dermatol Ther"},{"issue":"4","key":"977_CR108","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/jcm12041662","volume":"12","author":"G Avallone","year":"2023","unstructured":"Avallone G, Maronese CA, Murgia G, et al. Interleukin-17 vs. interleukin-23 inhibitors in pustular and erythrodermic psoriasis: a retrospective, multicentre cohort study. J Clin Med. 2023;12(4):1662. https:\/\/doi.org\/10.3390\/jcm12041662.","journal-title":"J Clin Med"},{"issue":"3","key":"977_CR109","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/1346-8138.16625","volume":"50","author":"H Liu","year":"2023","unstructured":"Liu H, Wei R, Yang Y, et al. Successful treatment with secukinumab of psoriasis-like dermatitis in a patient with holocarboxylase synthetase deficiency. J Dermatol. 2023;50(3):401\u20136. https:\/\/doi.org\/10.1111\/1346-8138.16625.","journal-title":"J Dermatol"},{"issue":"12","key":"977_CR110","doi-asserted-by":"publisher","first-page":"e1480","DOI":"10.1111\/jdv.19371","volume":"37","author":"A Reymundo","year":"2023","unstructured":"Reymundo A, Armesto S, Rodr\u00edguez L, et al. Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: multicentre study in daily practice. J Eur Acad Dermatol Venereol. 2023;37(12):e1480\u20132. https:\/\/doi.org\/10.1111\/jdv.19371.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"977_CR111","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.12773","volume":"29","author":"H Saeki","year":"2015","unstructured":"Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148\u201355. https:\/\/doi.org\/10.1111\/jdv.12773.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"977_CR112","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355\u201362. https:\/\/doi.org\/10.1111\/1346-8138.13622.","journal-title":"J Dermatol"},{"issue":"2","key":"977_CR113","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12825","volume":"32","author":"M Megna","year":"2019","unstructured":"Megna M, Gallo L, Balato N, Balato A. A case of erythrodermic psoriasis successfully treated with ixekizumab. Dermatol Ther. 2019;32(2): e12825. https:\/\/doi.org\/10.1111\/dth.12825.","journal-title":"Dermatol Ther"},{"issue":"2","key":"977_CR114","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14868","volume":"34","author":"E Trovato","year":"2021","unstructured":"Trovato E, Orsini C, Russo F, Cortonesi G, Rubegni P. Ixekizumab as treatment of erythrodermic psoriasis. Dermatol Ther. 2021;34(2): e14868. https:\/\/doi.org\/10.1111\/dth.14868.","journal-title":"Dermatol Ther"},{"key":"977_CR115","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4087","author":"A Vinaixa Aranzazu","year":"2021","unstructured":"Vinaixa Aranzazu A, Morillas-Lahuerta V, Blanco De Tord M, Carrascosa Carrillo JM. Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol. 2021. https:\/\/doi.org\/10.1684\/ejd.2021.4087.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"977_CR116","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s13555-021-00666-x","volume":"12","author":"A Morita","year":"2022","unstructured":"Morita A, Okubo Y, Morisaki Y, Torisu-Itakura H, Umezawa Y. Ixekizumab 80 mg every 2 weeks treatment beyond week 12 for japanese patients with generalized pustular psoriasis and erythrodermic psoriasis. Dermatol Ther (Heidelb). 2022;12(2):481\u201394. https:\/\/doi.org\/10.1007\/s13555-021-00666-x.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"11","key":"977_CR117","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15863","volume":"35","author":"EL Pinto-Pulido","year":"2022","unstructured":"Pinto-Pulido EL, Polo-Rodr\u00edguez I, Gonz\u00e1lez-Ca\u00f1ete M, Garc\u00eda-Verd\u00fa E, Piteiro-Bermejo AB, Medina-Montalvo S. Ixekizumab treatment for drug-induced erythrodermic psoriasis. Dermatol Ther. 2022;35(11): e15863. https:\/\/doi.org\/10.1111\/dth.15863.","journal-title":"Dermatol Ther"},{"issue":"3","key":"977_CR118","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741\u201351. https:\/\/doi.org\/10.1111\/bjd.14702.","journal-title":"Br J Dermatol"},{"issue":"6","key":"977_CR119","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14338","volume":"33","author":"N Bernardini","year":"2020","unstructured":"Bernardini N, Skroza N, Tolino E, et al. Recurrent erythrodermic psoriasis and polycythemia successfully treated with brodalumab. Dermatol Ther. 2020;33(6): e14338. https:\/\/doi.org\/10.1111\/dth.14338.","journal-title":"Dermatol Ther"},{"issue":"6","key":"977_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14351","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna M, Fabbrocini G, Ferrillo M, Cinelli E. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: report of two cases. Dermatol Ther. 2020;33(6): e14351. https:\/\/doi.org\/10.1111\/dth.14351.","journal-title":"Dermatol Ther"},{"issue":"6","key":"977_CR121","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ad.2022.10.048","volume":"114","author":"F Mota","year":"2023","unstructured":"Mota F, Mendes-Bastos P. Erythrodermic psoriasis successfully treated with brodalumab: a case series. Actas Dermosifiliogr. 2023;114(6):547\u20139. https:\/\/doi.org\/10.1016\/j.ad.2022.10.048.","journal-title":"Actas Dermosifiliogr"},{"issue":"12","key":"977_CR122","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15952","volume":"35","author":"M Valenti","year":"2022","unstructured":"Valenti M, Gargiulo L, Ibba L, Pavia G, Narcisi A, Costanzo A. Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report. Dermatol Ther. 2022;35(12): e15952. https:\/\/doi.org\/10.1111\/dth.15952.","journal-title":"Dermatol Ther"},{"issue":"3","key":"977_CR123","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jocd.15543","volume":"22","author":"M Megna","year":"2023","unstructured":"Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146\u20138. https:\/\/doi.org\/10.1111\/jocd.15543.","journal-title":"J Cosmet Dermatol"},{"issue":"8","key":"977_CR124","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/ijd.17109","volume":"63","author":"G Licata","year":"2024","unstructured":"Licata G, Rizzo D, Frazzitta M, Zichichi L. Successful treatment of sub-erythrodermic psoriasis with bimekizumab: a case report and literature review. Int J Dermatol. 2024;63(8):1105\u20137. https:\/\/doi.org\/10.1111\/ijd.17109.","journal-title":"Int J Dermatol"},{"issue":"5","key":"977_CR125","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529\u201339. https:\/\/doi.org\/10.1111\/1346-8138.14294.","journal-title":"J Dermatol"},{"issue":"2","key":"977_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13238","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna M, Ruggiero A, Camela E, Fabbrocini G, Marasca C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;33(2): e13238. https:\/\/doi.org\/10.1111\/dth.13238.","journal-title":"Dermatol Ther"},{"issue":"1","key":"977_CR127","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s13555-020-00480-x","volume":"11","author":"CY Chiang","year":"2021","unstructured":"Chiang CY, Tsai TF. Treatment response of patients with erythrodermic psoriasis after switching to guselkumab. Dermatol Ther (Heidelb). 2021;11(1):301\u20136. https:\/\/doi.org\/10.1007\/s13555-020-00480-x.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"977_CR128","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.abd.2023.05.007","volume":"99","author":"E Welsh","year":"2024","unstructured":"Welsh E, Cardenas-de la Garza JA, Garc\u00eda-Lozano JA, Flores-Gutierrez DP. Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review. An Bras Dermatol. 2024;99(2):319\u201320. https:\/\/doi.org\/10.1016\/j.abd.2023.05.007.","journal-title":"An Bras Dermatol"},{"issue":"6","key":"977_CR129","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/1346-8138.17255","volume":"51","author":"Y Tada","year":"2024","unstructured":"Tada Y, Sugiura Y, Kamishima M, et al. Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study. J Dermatol. 2024;51(6):779\u201390. https:\/\/doi.org\/10.1111\/1346-8138.17255.","journal-title":"J Dermatol"},{"issue":"5","key":"977_CR130","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40262-019-00829-2","volume":"59","author":"AA Suleiman","year":"2020","unstructured":"Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis. Clin Pharmacokinet. 2020;59(5):575\u201389. https:\/\/doi.org\/10.1007\/s40262-019-00829-2.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"977_CR131","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000525774","volume":"14","author":"A Alajlan","year":"2022","unstructured":"Alajlan A, Madani A, Qadoumi TA, Aljaloud A, Alessa M. Erythrodermic psoriasis managed with risankizumab. Case Rep Dermatol. 2022;14(2):219\u201324. https:\/\/doi.org\/10.1159\/000525774.","journal-title":"Case Rep Dermatol"},{"key":"977_CR132","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.2147\/CCID.S482737","volume":"16","author":"M Megna","year":"2024","unstructured":"Megna M, Ruggiero A, Salsano A, et al. A case of erythrodermic psoriasis successfully treated with risankizumab [published correction appears in Clin Cosmet Investig Dermatol. 2024 Jun 18;17:1447-1448. 10.2147\/CCID.S482737]. Clin Cosmet Investig Dermatol. 2024;16:3503\u20137. https:\/\/doi.org\/10.2147\/CCID.S482737.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"977_CR133","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15030","volume":"34","author":"M Megna","year":"2021","unstructured":"Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5): e15030. https:\/\/doi.org\/10.1111\/dth.15030.","journal-title":"Dermatol Ther"},{"issue":"4","key":"977_CR134","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.4081\/dr.2022.9448","volume":"14","author":"G Trevisan","year":"2022","unstructured":"Trevisan G, Germi L, Naldi L. Erythrodermic psoriasis improved by Tildrakizumab. Dermatol Rep. 2022;14(4):9448. https:\/\/doi.org\/10.4081\/dr.2022.9448.","journal-title":"Dermatol Rep"},{"issue":"6","key":"977_CR135","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1046\/j.1365-2133.1998.02296","volume":"138","author":"CC Geilen","year":"1998","unstructured":"Geilen CC, Tebbe B, Garcia Bartels C, Krengel S, Orfanos CE. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol. 1998;138(6):1101\u20132. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02296.","journal-title":"Br J Dermatol"},{"issue":"3","key":"977_CR136","first-page":"178","volume":"78","author":"TA Prossick","year":"2006","unstructured":"Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis. 2006;78(3):178\u201380.","journal-title":"Cutis"},{"issue":"15","key":"977_CR137","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.4103\/0366-6999.237411","volume":"131","author":"WM Wang","year":"2018","unstructured":"Wang WM, Wang KY, Wang T, Jin HZ, Fang K. Hydroxychloroquine-induced psoriasis-form erythroderma in a patient with systemic lupus erythematosus. Chin Med J (Engl). 2018;131(15):1887\u20138. https:\/\/doi.org\/10.4103\/0366-6999.237411.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"977_CR138","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3943","volume":"11","author":"EP Beltran Monasterio","year":"2019","unstructured":"Beltran Monasterio EP. Low-dose naltrexone: an alternative treatment for erythrodermic psoriasis. Cureus. 2019;11(1): e3943. https:\/\/doi.org\/10.7759\/cureus.3943.","journal-title":"Cureus."},{"issue":"2","key":"977_CR139","doi-asserted-by":"publisher","first-page":"1303\/qt4f8182b1","DOI":"10.5070\/D3272052387","volume":"27","author":"B Myers","year":"2021","unstructured":"Myers B, Reddy V, Brownstone N, Chan S, Thibodeaux Q, Koo J. The use of Goeckerman therapy in managing erythrodermic psoriasis resistant to multiple medications. Dermatol Online J. 2021;27(2):1303\/qt4f8182b1.","journal-title":"Dermatol Online J"},{"issue":"3","key":"977_CR140","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/archderm.1970.04000090066010","volume":"102","author":"CH Tay","year":"1970","unstructured":"Tay CH, Khoo OT. Papular mucinosis in chronic psoriatic erythroderma. Report of a case Arch Dermatol. 1970;102(3):304\u20138.","journal-title":"Report of a case. Arch Dermatol."},{"issue":"8","key":"977_CR141","first-page":"866","volume":"64","author":"A Macdonald","year":"1971","unstructured":"Macdonald A. Erythrodermic psoriasis with corneal ulcers and ophthalmological sequelae. Proc R Soc Med. 1971;64(8):866\u20138.","journal-title":"Proc R Soc Med"},{"issue":"5","key":"977_CR142","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2340\/0001555562446448","volume":"62","author":"H Zachariae","year":"1982","unstructured":"Zachariae H, Bjerring P. Methotrexate in psoriasis with and without leucovorin: effect of different dosage schedules on acute liver toxicity. Acta Derm Venereol. 1982;62(5):446\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"977_CR143","first-page":"169","volume":"36","author":"SA Spencer","year":"1985","unstructured":"Spencer SA, Fenske NA, Bookbinder SA, Vasey FB. Diflorasone diacetate ointment 0.05 percent in conjunction with UVB and tar in a modified outpatient Goeckerman regimen. Cutis. 1985;36(2):169\u201372.","journal-title":"Cutis"},{"issue":"4","key":"977_CR144","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.1997.tb03791.x","volume":"137","author":"S Muchenberger","year":"1997","unstructured":"Muchenberger S, Sch\u00f6pf E, Simon JC. The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br J Dermatol. 1997;137(4):587\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.1997.tb03791.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"977_CR145","first-page":"537","volume":"9","author":"C Roeder","year":"1999","unstructured":"Roeder C, Driesch PV. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol. 1999;9(7):537\u20139.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"977_CR146","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/039463200401700321","volume":"17","author":"C Franchi","year":"2004","unstructured":"Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol. 2004;17(3):401\u20136. https:\/\/doi.org\/10.1177\/039463200401700321.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"10","key":"977_CR147","first-page":"987","volume":"7","author":"GI Hernandez","year":"2008","unstructured":"Hernandez GI. Severe erythroderma in a patient under intermittent therapy with efalizumab. J Drugs Dermatol. 2008;7(10):987\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"977_CR148","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/039463200902200126","volume":"22","author":"V Bruzzese","year":"2009","unstructured":"Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis. Int J Immunopathol Pharmacol. 2009;22(1):235\u20138. https:\/\/doi.org\/10.1177\/039463200902200126.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6","key":"977_CR149","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/dht.13348","volume":"16","author":"A Romero-Mat\u00e9","year":"2010","unstructured":"Romero-Mat\u00e9 A, Garc\u00eda-Donoso C, Martinez-Mor\u00e1n C, Hern\u00e1ndez-N\u00fa\u00f1ez A, Borbujo J. Long-term management of erythrodermic psoriasis with anti-TNF agents. Dermatol Online J. 2010;16(6):15. https:\/\/doi.org\/10.1111\/dht.13348.","journal-title":"Dermatol Online J"},{"issue":"4","key":"977_CR150","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/qjmed\/hct139","volume":"107","author":"N Mumoli","year":"2014","unstructured":"Mumoli N, Vitale J, Gambaccini L, Sabatini S, Brondi B, Cei M. Erythrodermic psoriasis. QJM. 2014;107(4):315. https:\/\/doi.org\/10.1093\/qjmed\/hct139.","journal-title":"QJM"},{"key":"977_CR151","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1746-1596-9-102","volume":"9","author":"X Si","year":"2014","unstructured":"Si X, Ge L, Xin H, Cao W, Sun X, Li W. Erythrodermic psoriasis with bullous pemphigoid: combination treatment with methotrexate and compound glycyrrhizin. Diagn Pathol. 2014;9:102. https:\/\/doi.org\/10.1186\/1746-1596-9-102.","journal-title":"Diagn Pathol"},{"issue":"9","key":"977_CR152","first-page":"S77","volume":"27","author":"H Talat","year":"2017","unstructured":"Talat H, Wahid Z, Feroz F, Sajid M. Erythrodermic psoriasis and hepatitis C infection treated with pegylated interferon and anti-TNF\u03b1 \u03b1(Etanercept) Therapy. J Coll Physicians Surg Pak. 2017;27(9):S77\u20139.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"19","key":"977_CR153","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015433","volume":"98","author":"L Zhang","year":"2019","unstructured":"Zhang L, Xue S, Yu J, et al. IgA nephropathy associated with erythrodermic psoriasis: a case report. Medicine (Baltimore). 2019;98(19): e15433. https:\/\/doi.org\/10.1097\/MD.0000000000015433.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"977_CR154","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14222","volume":"33","author":"S Cretu","year":"2020","unstructured":"Cretu S, Salavastru CM, Tiplica GS. Treatment of psoriatic erythroderma using systemic corticosteroids: a timeless option? Dermatol Ther. 2020;33(6): e14222. https:\/\/doi.org\/10.1111\/dth.14222.","journal-title":"Dermatol Ther"},{"issue":"1","key":"977_CR155","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14704","volume":"34","author":"A Polat Ekinci","year":"2021","unstructured":"Polat Ekinci A, B\u00f6l\u00fck KN, Babuna KG. Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: a case series of high efficacy and safety profile. Dermatol Ther. 2021;34(1): e14704. https:\/\/doi.org\/10.1111\/dth.14704.","journal-title":"Dermatol Ther"},{"issue":"1","key":"977_CR156","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000018055","volume":"198","author":"H Maradit","year":"1999","unstructured":"Maradit H, Geiger JM. Potential risk of birth defects after acitretin discontinuation. Dermatology. 1999;198(1):3\u20134. https:\/\/doi.org\/10.1159\/000018055.","journal-title":"Dermatology"},{"issue":"4","key":"977_CR157","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0733-8635(18)30052-4","volume":"13","author":"J Koo","year":"1995","unstructured":"Koo J, Lee J. Cyclosporine: what clinicians need to know. Dermatol Clin. 1995;13(4):897\u2013907.","journal-title":"Dermatol Clin"},{"issue":"11","key":"977_CR158","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915. (PMID: 33349983).","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"977_CR159","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/14712598.2020.1776256","volume":"20","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Girolomoni G. Brodalumab in the treatment of chronic plaque psoriasis. Expert Opin Biol Ther. 2020;20(10):1175\u201386. https:\/\/doi.org\/10.1080\/14712598.2020.1776256.","journal-title":"Expert Opin Biol Ther"},{"key":"977_CR160","doi-asserted-by":"publisher","first-page":"adv00821","DOI":"10.2340\/actadv.v102.1982","volume":"102","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Dapavo P, Trunfio M, et al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a Tertiary Care Centre in Northern Italy. Acta Derm Venereol. 2022;102:adv00821. https:\/\/doi.org\/10.2340\/actadv.v102.1982.","journal-title":"Acta Derm Venereol"},{"issue":"21","key":"977_CR161","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.3390\/jcm13216546","volume":"13","author":"N Macagno","year":"2024","unstructured":"Macagno N, Mastorino L, Ortoncelli M, et al. Drug survival and clinical course of patients with cancer treated with biologic therapy for psoriasis. J Clin Med. 2024;13(21):6546. https:\/\/doi.org\/10.3390\/jcm13216546.","journal-title":"J Clin Med"},{"issue":"4","key":"977_CR162","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/14712598.2024.2337242","volume":"24","author":"S Boskovic","year":"2024","unstructured":"Boskovic S, Borriello S, D\u2019Ascenzo F, et al. Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk. Expert Opin Biol Ther. 2024;24(4):217\u20139. https:\/\/doi.org\/10.1080\/14712598.2024.2337242.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"977_CR163","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1111\/jdv.18314","volume":"36","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Castelli F, Stroppiana E, et al. Risankizumab shows faster response in bio na\u00efve than in bio-experienced psoriatic patients. J Eur Acad Dermatol Venereol. 2022;36(10):e838\u201341. https:\/\/doi.org\/10.1111\/jdv.18314.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00977-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:14:46Z","timestamp":1775114086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00977-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":163,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00977-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"30 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has revised due to update in funding information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No ethical approval needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"No consent needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"No consent needed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}